Prognostic Significance of Lymphoid Enhancer-Binding Factor-1 Expression in Egyptian Adult B-Acute Lymphocytic Leukemia Patients

Mısırlı Yetişkin Akut B Lenfoblastik Lösemi Hastalarında Görülen Lenfoid Enhansır-Bağlayıcı Faktör-1 Ekspresyonunun Prognostik Önemi

Rabab M. Aly¹, Ansaf B. Yousef²
¹Mansoura University Faculty of Medicine, Department of Clinical Pathology, Mansoura, Egypt
²Mansoura University Faculty of Medicine, Department of Internal Medicine, Mansoura, Egypt

Abstract:

Objective: Lymphoid enhancer-binding factor-1 (LEF-1) is a key transcription factor of wingless-type (Wnt) signaling in various tumors and it is associated with a number of malignant diseases such as leukemia. We explored the expression profile of LEF-1 in acute lymphoblastic leukemia (ALL) and determined its specific prognostic significance in this disease.

Materials and Methods: We studied LEF-1 expression in 56 newly diagnosed B-acute ALL adult patients using real-time quantitative polymerase chain reaction to investigate whether LEF-1 expression was associated with clinical patient characteristics and treatment outcomes.

Results: High LEF-1 expression was associated with significantly poorer disease-free survival (p=0.03) and overall survival (p=0.005). Patients with high LEF-1 expression had a significantly higher relapse rate compared with low LEF-1 expression (p=0.01).

Conclusion: We provide evidence that high LEF-1 expression is a prognostic marker in adult B-acute ALL patients.

Key Words: Lymphoid enhancer-binding factor-1, Acute lymphoblastic leukemia, Prognosis, Wnt

Özet:

Amaç: Lenfoid enhansır-bağlayıcı faktör-1 (LEF-1), çeşitli tümörlerde wingless-type (Wnt)'yi işaret eden ana transkripsiyon faktörü olmakla birlikte lösemi gibi birçok ölümcül hastalığı da ilişkilendirilir. Biz bu çalışmada, LEF-1’in akut lenfoblastik lösemi hastalarında ekspresyon profili araştırdık ve LEF-1'in bu hastalığın genelindeki özel prognostik önemi saptadık.

Gereç ve Yöntemler: B-ALL hastaları tanısı yeni konmuş 56 yetişkin hastada LEF-1 ekspresyonunu çalıştık ve LEF-1 ekspresyonunun klinik hastalik özellikleriyle ve tedavi sonuçlarıyla ilişkili olup olmadığı araştırmak için gerçek-zamanlı kanitlatıcı polimeraz zincir reaksiyonu uyguladık.

Address for Correspondence: Rabab M. ALY, M.D., Mansoura University Faculty of Medicine, Department of Clinical Pathology, Mansoura, Egypt
E-mail: rabahzeada@yahoo.com

Received/Geliş tarihi : April 18, 2013
Accepted/Kabul tarihi : September 27, 2013
Bulgular: Yüksek LEF-1 ekspresyonu olan hastalarda hastalık şıkmaz sağkalım (p=0,03) ve genel sağkalım (p=0,005) daha kısaydı. Düşük LEF-1 ekspresyonlu hastalara kuyaslandığında, yüksek LEF-1 ekspresyonunu hastalarda anlamli olarak daha yüksek nüks oranları gözlandi (p=0,01).

Sonuç: Bu çalışma sonucunda, yüksek LEF-1 ekspresyonunun yetişkin B-ALL hastalarında prognostik belirteç olduğuguna yönelik kanıt sunuyoruz.

Anahtar Sözcükler: Lenfoid enhansır-bağlayıcı faktör-1, Akut lenfoblastik lösemi, Prognoz, Wnt

**Introduction**

The outcome of adult B-precursor acute lymphoblastic leukemia (B-ALL) has considerably improved because of identification of clinical and genetic risk factors stratifying patients into different treatment groups [1]. Common risk factors in B-ALL include white blood cell (WBC) count, the immunophenotype of B-ALL, response to induction therapy, level of minimal residual disease, age, and cytogenetic as well as molecular genetic aberrations [2]. High-risk cytogenetics in B-ALL mainly comprise the Philadelphia chromosome with balanced translocation t(9; 22) (q34; q11) and the BCR-ABL fusion gene in approximately 20% to 36% of cases [3] and translocation t(4; 11) (q21; q23) with the MLL-AF4 fusion gene in approximately 6% to 9% of cases [4]. Patients lacking clinical and molecular risk factors are considered to be of standard risk. The relapse rate is still approximately 40% to 50% and relapse is not predictable with pretreatment markers in the standard-risk patient group without established risk factors [5,6].

The identification of new prognostic factors is of particular interest for this subgroup of ALL. Moreover, it may help to develop novel targeted therapies for these patients. It was previously demonstrated that ordered expression of lymphoid enhancer-binding factor-1 (LEF-1) is necessary for normal hematopoietic stem cell function in mice, and that LEF-1 overexpression induces acute myeloid leukemia (AML) [7]. LEF-1 plays a crucial role in the development of hematopoietic tissues [15]. The human LEF-1 gene spans at least 140 kb and contains 12 exons and 11 introns, with a large third intron (about 75 kb) that may contain an alternative exon. The LEF-1 gene encodes at least 2 isoforms. LEF-1 is a sequence-specific DNA binding protein that binds to a functionally important site in the T-cell receptor-alpha enhancer through an HMG domain and confers maximal enhancer activity [22].

**Materials and Methods**

**Patients**

Fifty-six Egyptian patients (43 males and 13 females) were diagnosed with B-ALL at the Oncology Center of Mansoura University Hospital were enrolled in this study. The study was approved by the Institutional Review Board of the Mansoura University Hospital. All patients gave informed consent to morphological and molecular examination. Diagnosis of ALL was based on morphologic and immunophenotypic criteria. Heparinized bone marrow (BM) and peripheral blood samples were collected prior to treatment. Minimal residual disease was effectively monitored by use of BM samples. Clinical and hematological parameters were determined. All included patients received the same treatment protocol, approved by the oncology team of the oncology center. It included 6 weeks of induction, 2 weeks of consolidation, and 120 weeks of continuation therapy. Induction therapy consisted of vincristine (VCR), daunomycin, asparaginase, etoposide (VP-16), and aracytin (Ara-C) in addition to triple intrathecal (IT) therapy including 2 courses of high-dose methotrexate (HDMTX), 6-mercaptopurine (6-MP), and dexamethasone (Dex). Continuation therapy consisted of extended triple IT therapy and 15 cycles of an 8-week course of VP-16+cyclophosphamide (CTX), 6-MP+MTX, MTX+Ara-C, Dex+VCR, VP-16+Ara-C, 6-MP+HDMTX, VP-16+Ara-C, and...
PCR Ct value, which is the cycle number at which emitted fluoresence exceeds 10 times the standard deviation of baseline emissions, was normalized to the GAPDH PCR Ct value by subtracting the GAPDH Ct value from the target PCR Ct value. The mRNA expression level relative to GAPDH for each target PCR was calculated using the following equation: relative mRNA expression = $2^{-\frac{(Ct\ target-Ct\ GAPDH)}{}}$.

Statistical Analysis

SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for all calculations. Clinical features across groups were compared using the $\chi^2$ or 2-sided Fisher exact test for categorical data and the nonparametric Mann-Whitney U test for continuous variables. Survival curves were calculated by the Kaplan-Meier method. Multivariate analyses were performed using the Cox proportional hazards model for survival, including the following variables in the full model: LEF-1 expression, age, WBC count, and immunophenotype. P<0.05 was considered statistically significant.

Results

We determined LEF-1 expression in 56 patients with newly diagnosed B-ALL. There were no significant correlations between LEF-1 expression levels and clinical, laboratory, or immunophenotypic characteristics (Table 1). Based on the detection of LEF-1 median expression level (1.73), patients were divided into the low-expression group (LEF-1 expression level of <1.73) and high-expression group (LEF-1 expression level of >1.73).

In the Cox regression analysis, LEF-1 expression was the most significant prognostic factor for disease-free survival (DFS) (p=0.001); the other significant factors predicting DFS were age and immunophenotype (Table 2).

We analyzed the influence of LEF-1 expression on the prognosis of B-ALL patients. Patients with high LEF-1 expression, as compared to patients with low LEF-1 expression, showed significantly lower remission rates (p=0.02). Patients with high LEF-1 expression were significantly associated with a higher relapse rate (p=0.01, Table 3).

Table 3 also showed that, at 3 years, the estimated overall survival (OS) was 58.9% in patients with low LEF-1 expression, which was higher than in patients with high expression (33.9%) (p=0.005). Adverse prognosis associated with high LEF-1 expression was observed in terms of 3-year DFS (high LEF-1, 23.4% vs. low LEF-1 expression, 51.0%; p=0.03).

Discussion

The prognostic markers in B-ALL have a significantly important role in the development of new molecular therapies for these patients. In the current study, we have used a
quantitative real-time PCR assay to analyze the role of LEF-1 expression in patients with B-ALL.

In this study, we have identified high LEF-1 expression as an independent prognostic factor associated with a high risk of relapse and lower DFS in B-ALL patients. High LEF-1 expression was independently prognostic for lower OS, with a 3-year survival rate of only 33.9% for patients with high LEF-1 expression compared to 58.9% in the patient group with low LEF-1.

Several studies found effects of LEF-1 expression on the degree of malignancy in neoplastic diseases. LEF-1 appears to mediate tumor growth and invasion ability in androgen-independent prostate cancer [25]. Moreover, Nguyen et al. found that LEF-1 also mediates cell invasion in breast cancer [26]. Deregulated LEF-1 expression may also be an important step in the development of neoplastic diseases. LEF-1 is involved in B and T lymphocyte development [8]. The diverse functions of LEF-1 in normal and malignant hematopoiesis are reflected by recent reports that high LEF-1 expression is associated with inferior outcomes in B-ALL [28]. Metzeler et al. reported a larger increase of the expression of LEF-1 in ALL samples than in AML, reflecting the higher expression of the transcription factor in lymphoid tissue [29]. Several studies found that deregulated expression of LEF-1 could induce B-ALL [7,8].

Our study showed no significant association of clinical characteristics and high LEF-1 expression. Conversely, in patients with T-ALL, LEF-1 was characterized by distinctive clinical features, including a younger age at diagnosis and a trend toward improved OS in children treated with contemporary T-ALL combination therapy [30].

Current risk stratification is based primarily on clinical variables, immunophenotyping, detection of cytogenetic or molecular lesions, and early response to therapy [31]. Importantly, our study shows that high LEF-1 expression was also associated with poor DFS. This was in agreement with Kühnl et al., who found that high LEF-1 expression identifies B-ALL patients with inferior DFS [28].

In multivariate analysis, the association between LEF-1 expression and outcome showed that high LEF-1 expression was associated with poor DFS. This was in agreement with Kühnl et al., who found that high LEF-1 expression identifies B-ALL patients with inferior DFS [28].

Table 1. LEF-1 expression and clinical characteristics in acute lymphoblastic leukemia (ALL) cases.

|                                | High LEF-1 (n=22) | Low LEF-1 (n=34) | p   |
|--------------------------------|-------------------|------------------|-----|
| Age (years)                    |                   |                  |     |
| Median                         | 45                | 38               | 0.09|
| Range                          | 18-49             | 19-46            |     |
| Sex (%)                        |                   |                  |     |
| Male                           | 68.1              | 70.5             | 0.73|
| Immunophenotype                |                   |                  |     |
| Precursor B-ALL                | 15 (68.2%)        | 25 (73.5%)       | 0.07|
| Common ALL                     | 7 (31.8%)         | 9 (26.5%)        |     |
| WBC count (x10^9/L)            |                   |                  |     |
| Median                         | 32                | 29               | 0.07|

Table 2. Multivariate analysis of LEF-1 expression for disease-free survival (DFS) in acute lymphoblastic leukemia (ALL) patients.

|                                 | HR    | 95% CI    | p   |
|---------------------------------|-------|-----------|-----|
| Age                             | 0.9   | 0.7-1.2   | 0.04|
| WBCs                            | 1.3   | 0.6-1.5   | 0.06|
| Immunophenotype                 |       |           |     |
| Precursor B-ALL vs. common ALL  | 1.7   | 1.2-1.9   | 0.02|
| LEF-1 expression                |       |           |     |
| High vs. low                    | 3.1   | 1.7-4.3   | 0.001|

Table 3. LEF-1 expression and clinical outcome.

|                                | High LEF-1 expression | Low LEF-1 expression | p   |
|--------------------------------|-----------------------|---------------------|-----|
| Complete response, CR/total, no. (%) | 16/22 (72.7)         | 31/34 (91.1)       | 0.02|
| Relapse, Relapse/total, no. (%)    | 9/16 (56.2)          | 11/31 (35.4)       | 0.01|
| 3-year Overall survival, % (n=56) | 33.9                 | 58.9               | 0.005|
| 3-year Disease-free survival, % (n=47) | 23.4             | 51.0               | 0.03|
expression is more significant than other prognostic factors for DFS, such as for age, leukocyte count at presentation, or immunophenotype; this indicates that high LEF-1 expression at diagnosis might be useful in identifying patients with a high risk of treatment failure.

A study of T-ALL patients with inactivating LEF-1 mutations showed a trend toward a favorable OS [30]. Conversely, in patients with myelodysplastic syndrome, advanced disease and poor prognosis were associated with downregulation of LEF-1, probably reflecting the impaired maturation of myeloid progenitors associated with loss of LEF-1 function [15,32]. In leukemic cells, LEF-1 enhanced self-renewal properties and survival in vitro and was shown to confer leukemogenic potential in a mouse model [7,12,15]. Furthermore, patients with high LEF-1 expression should be considered for new molecular directed therapies, especially agents targeting the Wnt pathway [33].

In summary, we provide evidence that high LEF-1 expression has adverse prognostic significance and thus may provide a valuable new approach to molecular-targeted therapy in B-ALL patients.

**Conflict of Interest Statement**

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

**References**

1. Gökbüget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009;46:64-75.
2. Rowe JM. Optimal management of adults with ALL. Br J Haematol 2009;144:468-483.
3. Burmeister T, Schwartz S, Bartram CR, Gökbüget N, Hoelzer D, Thiel E, GMLL study group. Patients’ age and BCR/ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMLL study group. Blood 2008;112:918-919.
4. Thomas X, Boiron JM, Huguet F, Domhret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tourmilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lherrtier V, Fiere D. Outcome of treatment in adults with acute lymphoblastic leukaemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075-4086.
5. Gökbüget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M, Ganser A, Kneba M, Langer W, Lipp T, Ludwig WD, Maschmeyer G, Rieder H, Thiel E, Weiss A, Messerer D. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMLL). Hematol Oncol Clin North Am 2000;14:1307-1325.
6. Brüggemann M, Raff T, Flohr T, Gökbüget N, Nakao M, Droese J, Lüschen S, Pott C, Rügten M, Scheuring U, Horst HA, Thiel E, Hoelzer D, Bartram CR, Kneba M; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:1116-1123.
7. Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ, Heilmeyer B, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med 2008;205:515-522.
8. Reya T, O’Riordan M, Okamura R, Devaney E, Willert K, Nusse R, Grosschedl R. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000;13:15-24.
9. Skokowa J, Cario G, Uenalan M, Schambach A, Germeshausen M, Battmer K, Zeidler C, Lehmann U, Eder M, Baum C, Grosschedl R, Stanulla M, Scherr M, Welte K. LEF-1 is crucial for neutrophil granulopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 2006;12:1191-1197.
10. Gelebart P, Anand M, Armanious H, Peters AC, Diem Bard J, Amin HM, Lai R. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008;112:5171-5179.
11. Spaulding C, Reschly EJ, Zagort DE, Yashiro-Ohtani Y, Beverly LJ, Capobianco A, Pear WS, Kee BL. NotchI co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood 2007;110:2650-2658.
12. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM 3rd, Slager SL, Kay NE, Jelinek DE. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukemia. Acta Biochim Biophys Sin (Shanghai) 2005;37:173-180.
13. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukemia. Oncogene 2005;24:2410-2420.
14. Wang W, Ji P, Steffen B, Metzger R, Schneider PM, Haffter H, Schrader M, Berdel WE, Serve H, Müller-Tidow C. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. Acta Biochim Biophys Sin (Shanghai) 2005;37:173-180.
15. Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Köhler G, Stelljes M, Puccetti E, Rathardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004;24:2890-2904.
16. Nawshad A, Hay ED. TGFβ3 signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation during mouse palate development. J Cell Biol 2003;163:1291-1301.

17. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512.

18. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-480.

19. Gehrke I, Gandhirajan RK, Kreuzer KA. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: multiplicity of therapeutic options. Eur J Cancer 2009;45:2759-2767.

20. Khan NI, Bradstock KE, Bendall LJ. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukemia. Br J Haematol 2007;138:338-348.

21. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2004;101:3118-3123.

22. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe RE, Waterman ML. β-Catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001;28:53-57.

23. Lanzokowsky PH. Leukemia. In: Lanzokowsky P (ed). Manual of Pediatric Hematology and Oncology. 2nd ed. New York, Churchill Livingstone, 2005.

24. Meijerink J, Mandigers C, van de Locht L, Tönsmien E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real time PCR. J Mol Diagn 2001;3:55-61.

25. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X, Pellicer A, Garabedian MJ, Ferrari A, Lee P. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res 2009;69:3332-3338.

26. Nguyen A, Rosner A, Milovanovic T, Hope C, Planutis K, Saha B, Chauvin B, Lin F, Imam SA, Marsh JL, Holcombe RE. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression. Int J Oncol 2005;27:949-956.

27. Okamura RM, Sigvardsson M, Galceran J, Verbeek S, Clevers H, Grosschedl R. Redundant regulation of T cell differentiation and TCRα gene expression by the transcription factors LEF-1 and TCF-1. Immunity 1998;8:11-20.

28. Kühl A, Gökbüget N, Kaiser M, Schlee C, Streu X, Burmeister T, Moehmann LH, Hoeltzer D, Hofmann WK, Thiel E, Baldus CD. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood 2011;118:6362-6367.

29. Metzeler KH, Heilmeyer B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Speikermann K, Böchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 2012;120:2118-2126.

30. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borrow MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010;115:2845-2851.

31. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet 2008;371:1030-1043.

32. Pellagatti A, Marafioti T, Paterson JC, Malcovati L, Della Porta MG, Jädersten M, Pushkaran B, George TI, Arber DA, Killick S, Giagounidis A, Hellström-Lindberg E, Cazzola M, Wainscoat JS, Bottlewood J. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 2009;146:86-90.

33. Minke KS, Staib P, Puepter A, Gehrke I, Gandhirajan RK, Schlösser A, Schmitt EK, Hallek M, Kreuzer KA. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 2009;82:165-175.